Table 1 Perception of teratogenicity among GP and OB/GYN responders according to drug
Drug | GP responders | OB/GYN responders | p-valuea |
|---|---|---|---|
Median & [50 %] and 90 % IPR | Median & [50 %] 90 % IPR | ||
Acetaminophen | 2.0 [1.0–5.0]; 0.4–16 | 2.5 [1.0–4.0]; 0.5–5.0 | 0.41 |
Phenoxymethylpenicillin | 2.0 [1.0–5.0]; 0.1–6.0 | 2.0 [1.0–3.0]; 0,1–5,0 | 0.29 |
Metoclopramide | 3.0 [1.0–5.0]; 0.20–7.0 | 2.0 [1.0–4.0]; 0.5–5.0 | 0.02 |
Citalopram/sertraline | 4.0 [2.0–6.0]; 0.8–10.0 | 3.0 [2.0–5.0]; 0.5–6.0 | 0.02 |
Benzodiazepines | 3.0 [1.0–5.0]; 0.5–8.0 | 2.5 [1.0–4.0]; 0.5–5.0 | 0.03 |
Inhaled glucocorticoids | 3.0 [1.0–5.0]; 0.2–5.5 | 2.0 [1.0–3.0]; 0.5–5.0 | 0.54 |
Fluconazole | 3.0 [1.5–5.0]; 0.5–7.0 | 2.5 [1.1–4.0]; 0.5–6.0 | 0.45 |
Quetiapine | 5.0 [2.0–7.0]; 1.0–10 | 3.0 [1.5–5.0]; 0.5–6.0 | 0.001 |
Lamotrigine | 5.0 [2.1–6.0]; 1.0–12 | 4.0 [2.0–5.0]; 0.6–7.0 | 0.25 |
Thalidomide | 20 [10–50]; 5.0–60 | 20 [9.0–45]; 5.0–50 | 0.14 |
Warfarin | 3.0 [1.5–5.0]; 0.5–10 | 5.0 [2.1–7.0]; 1.0–15 | 0.01 |
Retinoids | 10 [5.0–20]; 1.6–50 | 5.0 [2.1–10]; 1.0–30 | 0.001 |
Background incidence | 2.0 [0.5–4.0]; 0.02–5.0 | 2.0 [1.0–3.0]; 0.03–4.0 | 0.36 |